Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00429182 · ClinicalTrials.gov registry record · Phase 2

Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
32
Enrollment target

NCT00429182: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00429182 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00429182, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
32 participants
Enrollment target

Study Summary

The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.

Primary Outcome

Number of circulating tumor cells (CTCs) measured at one month post autologous hematopoietic stem cell transplantation (AHST), considered both as longitudinal values and compared to the baseline number of CTCs.

Interventions

  • DRUG Cyclophosphamide
  • DRUG Carboplatin
  • DRUG Thiotepa
  • PROCEDURE Stem Cell Transplant

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2007-06
Est. Completion 2012-02
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00429182 record still lists

NCT00429182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (76% lower).

The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.

NCT00429182 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00429182 about?

NCT00429182 is a clinical study titled "Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer". The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.

What is the current status of trial NCT00429182?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-06. Estimated completion is 2012-02.

What interventions are being tested in trial NCT00429182?

The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Thiotepa (DRUG), Stem Cell Transplant (PROCEDURE).

Who is sponsoring clinical trial NCT00429182?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00429182's enrollment target sits among peer trials

32 1563rd of 2000 higher than 423 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00429182, the US trial registry maintained by the National Library of Medicine. NCT00429182 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.